BARDA-sponsored Phase 2 H5 flu vaccine trial posts results comparing AS03 and MF59 adjuvants
Results were posted for a completed Phase 2 study testing egg-based H5N8 and H5N1 vaccines at varying antigen doses with AS03 or MF59 adjuvants in adults.
This week's single item covers a BARDA-funded Phase 2 influenza vaccine study that has completed and posted results.
- NCT06560151 is a Phase 2, randomized, double-blind study sponsored by the Biomedical Advanced Research and Development Authority, with Rho Federal Systems Division, Inc. and ICON plc as collaborators. The trial tested egg-based H5N8 and H5N1 influenza vaccines across three antigen dose levels, 3.75, 7.5, and 15 μg, paired with either a full dose of AS03, a half dose of AS03 for the H5N8 vaccine only, or MF59.1 The study enrolled about 1380 healthy adults, split between 780 participants aged 18 to 64 and 600 participants aged 65 and older, each receiving two vaccine doses 21 days apart.1 The trial's status shows a start date of August 21, 2024, primary completion of January 16, 2025, and study completion of June 11, 2025, with results first posted July 23, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.